Efficacy and safety of reslizumab in adjuvant therapy for patients with refractory asthma: a meta-analysis
10.3760/cma.j.cn114015-20220824-00774
- VernacularTitle:瑞利珠单抗辅助治疗难治性哮喘疗效和安全性的meta分析
- Author:
Manru CHEN
1
;
Cuilyu LIANG
;
Yin ZHANG
;
Qiying CHEN
;
Caiyun CHEN
Author Information
1. 福建医科大学附属第二医院药学部，泉州 362000
- Publication Type:Journal Article
- Keywords:
Interleukin-5;
Asthma;
Efficiency;
Safety;
meta-analysis;
Reslizumab
- From:
Adverse Drug Reactions Journal
2023;25(5):299-307
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate the efficacy and safety of reslizumab targeting interleukin 5 in adjuvant therapy for patients with refractory asthma.Methods:The PubMed, Embase, Cochrane Library, Clinicaltrials.gov, CNKI, VIP, and Wanfang databases were searched (up to June 2022). Randomized controlled trials (RCTs) of reslizumab in adjuvant therapy of refractory asthma were collected. On the basis of conventional treatment for asthma, patients in the trial group was given additional reslizumab while the control group was given placebo. Primary outcome measures included the acute asthma attacks incidence, the changes of forced expiratory volume in the first second (FEV 1), asthma control questionnaire (ACQ) score, asthma quality of life questionnaire (AQLQ) score, and blood eosinophil count before and after adjuvant therapy, and incidence of adverse events. RevMan 5.3 software was used for meta-analysis. The effect sizes of counting data were odds ratio ( OR) and its 95% confidence interval ( CI), while the effect sizes of measurement data were mean difference ( MD) and its 95 %CI. Results:A total of 7 RCTs and 2 506 patients were entered in the analysis, including 1 456 in the trial group and 1 050 in the control group. The meta-analysis showed that, compared to the control group, the acute asthma attacks incidence was lower in patients of the trial group during adjuvant therapy[18.1%(263/1 456) vs. 31.3%(329/1 050), OR=0.50, 95 %CI: 0.41-0.62, P<0.001]; FEV1 and AQLQ score after treatment were higher ( MD=0.13 L, 95 %CI: 0.08-0.17 L, P<0.001; MD=0.18, 95 %CI: 0.04-0.33, P=0.01); the ACQ score and blood eosinophil count were higher ( MD=-0.19, 95 %CI: -0.28--0.10, P<0.001; MD=-0.45×10 9/L, 95 %CI:-0.48×10 9/L--0.42×10 9/L, P<0.001). There were no statistically significant difference in the incidences of overall adverse events, serious adverse events, allergic reactions, and pneumonia compared to those in the control group [63.7% (928/1 456) vs. 71.4% (750/1 050), OR=0.76, 95 %CI: 0.55-1.06, P=0.10; 6.4% (93/1 456) vs. 8.2% (86/1 050), OR=0.91, 95 %CI: 0.66-1.24, P=0.55; 0.4% (5/1 403) vs. 0.1% (1/997), OR=1.66, 95 %CI: 0.41-6.65, P=0.47; 0.6% (9/1 456) vs. 1.0% (10/1 050), OR=0.81, 95 %CI: 0.35-1.87, P=0.63]. Conclusion:Reslizuma has a good efficacy and safety profile in adjuvant treatment for patients with refractory asthma.
